Hub : Traits :

Schizophrenia (2018)

482 significantly associated models · 131 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 35925590 37340877 1 1 2.1e-08 6.5e-08 1.0e+00 100 MAP7D1
2 1 242590540 244359621 3 3 3.1e-10 1.3e-08 7.9e-01 100 AKT3 CEP170 SDCCAG8
3 2 197134790 199079806 4 2 6.7e-11 4.0e-09 3.5e-01 98 ANKRD44 HSPD1
4 2 200086752 201571143 4 1 2.4e-12 2.1e-10 7.4e-02 92 C2orf47
5 2 224636490 226142508 1 1 5.5e-09 1.3e-06 4.4e-01 98 CUL3
6 3 1442951 3792945 1 1 2.3e-08 4.9e-10 1.2e-04 62 CNTN4
7 3 36235084 37614424 1 1 2.7e-07 7.6e-10 4.5e-04 68 AC011816.1
8 3 51655856 53560321 8 1 1.1e-08 3.7e-08 2.0e-01 95 ITIH4-AS1
9 3 63121945 64546545 1 1 2.8e-09 4.2e-09 1.0e+00 100 THOC7
10 3 135273949 137261517 4 1 2.5e-09 3.4e-09 1.0e+00 100 PCCB
11 4 169845720 171339965 1 1 1.9e-07 6.8e-08 1.2e-03 64 CLCN3
12 5 59474215 60936935 1 1 5.5e-09 2.2e-10 6.1e-03 81 ERCC8
13 5 100875868 102327463 1 1 2.0e-07 6.3e-07 7.0e-01 99 SLCO4C1
14 5 136972187 138380480 1 1 5.1e-10 2.1e-08 6.2e-03 76 FAM53C
15 5 139329962 140784895 5 1 1.5e-08 3.4e-07 4.0e-01 97 IK
16 6 24300846 24891985 1 1 2.9e-11 4.0e-05 6.5e-01 99 KIAA0319
17 6 25266147 26689223 2 2 1.1e-11 2.8e-21 8.2e-07 73 TRIM38 U91328.21
18 6 63737627 64273105 1 1 7.1e-09 1.8e-06 1.8e-01 92 LGSN
19 7 109603832 111895681 1 1 1.4e-08 2.0e-10 1.1e-03 74 IMMP2L
20 8 142839492 145286483 2 2 5.6e-08 4.7e-09 4.1e-05 51 BAI1 FAM83H
21 10 103313599 106042502 13 1 9.1e-17 2.7e-15 8.0e-01 100 AS3MT
22 11 45945837 47902883 6 1 2.6e-08 1.4e-09 1.0e+00 100 ATG13
23 11 63316786 64707978 1 1 5.6e-09 3.1e-06 8.6e-02 86 PPP1R14B
24 12 1204676 2805632 2 2 4.9e-10 1.3e-13 8.2e-05 72 CACNA2D4 DCP1B
25 12 110175537 111634281 2 1 5.2e-08 5.4e-09 2.6e-02 85 VPS29
26 12 122713991 124545118 9 1 1.8e-09 2.0e-09 2.4e-02 86 C12orf65
27 14 70676661 72273020 1 1 4.4e-09 2.9e-08 8.1e-01 100 PCNX
28 14 103161201 105211221 11 1 4.3e-11 5.8e-10 3.3e-02 88 PPP1R13B
29 15 78135979 79537269 2 1 3.6e-12 2.2e-12 1.0e+00 100 CHRNA5
30 15 84151637 86040394 10 1 1.6e-10 9.2e-10 5.5e-01 99 AC103965.1
31 15 90718541 92135418 3 1 1.0e-13 4.6e-12 3.8e-03 82 FES
32 16 28845251 30823047 3 1 5.9e-08 2.6e-07 9.0e-01 100 MAPK3
33 17 12198253 13613997 1 1 2.8e-07 3.9e-06 4.8e-01 98 ELAC2
34 17 17017584 18325085 4 1 2.6e-08 7.9e-08 1.0e+00 100 C17orf39
35 20 36681910 38094711 1 2 1.3e-08 5.4e-12 6.3e-04 75 ACTR5
36 22 39192995 40571499 1 1 1.1e-08 1.6e-09 4.4e-03 78 MGAT3
37 22 41641984 43232818 10 1 5.2e-09 7.8e-09 1.3e-02 82 NAGA
38 22 50070991 50559247 1 1 7.0e-08 1.1e-06 6.8e-01 99 CRELD2

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 4.13 4 2 4.4 1.00 1.4e-03 AC103965.1 CACNA2D4 ITIH4-AS1 PPP1R14B
Bipolar Disorder or Schizophrenia 14.93 42 30 66.7 0.99 2.5e-35 AC011816.1 AC103965.1 ACTR5 AKT3 ANKRD44 AS3MT ATG13 BAI1 C12orf65 C17orf39 C2orf47 CACNA2D4 CEP170 CHRNA5 CLCN3 CNTN4 CRELD2 CUL3 DCP1B ELAC2 ERCC8 FAM53C FES HSPD1 IK IMMP2L ITIH4-AS1 KIAA0319 LGSN MAP7D1 MAPK3 MGAT3 NAGA PCCB PCNX PPP1R13B PPP1R14B SDCCAG8 SLCO4C1 THOC7 TRIM38 U91328.21
Depressed Affect (Nagel 2018) 1.59 2 0 0.0 0.00 1.0e+00 CEP170 PCCB
Depression (Nagel 2018) 1.94 1 0 0.0 0.00 1.0e+00 PCCB
Intelligence (Savage-Jansen 2018) 2.66 6 2 4.4 -0.69 1.3e-01 C12orf65 IK IMMP2L ITIH4-AS1 MGAT3 PCCB
Neuroticism (Nagel 2018) 1.90 2 1 2.2 0.00 1.0e+00 AS3MT PCCB
Schizophrenia vs Biploar Disorder 3.56 3 0 0.0 0.00 1.0e+00 ATG13 C17orf39 VPS29
Worry (Nagel 2018) 3.26 8 3 6.7 0.98 3.5e-05 AS3MT C2orf47 CACNA2D4 ITIH4-AS1 MAPK3 PCCB THOC7 TRIM38
Major Depression (MDD) 2.47 1 0 0.0 0.00 1.0e+00 MAP7D1
Reaction Time 2.00 3 1 2.2 0.00 1.0e+00 ATG13 C2orf47 IMMP2L
Verbal and Numeric Reasoning (VNR) 3.11 5 2 4.4 -0.99 6.0e-04 IK ITIH4-AS1 MGAT3 NAGA U91328.21
Breast Cancer 1.44 1 1 2.2 0.00 1.0e+00 FES
Prostate Cancer 1.51 1 0 0.0 0.00 1.0e+00 FAM83H
Bipolar Disorder (2011) 4.58 2 0 0.0 0.00 1.0e+00 CACNA2D4 ITIH4-AS1
Coronary Artery Disease (CAD) 1.62 2 0 0.0 0.00 1.0e+00 AS3MT C17orf39
Crohns Disease (2012) 1.20 1 0 0.0 0.00 1.0e+00 CRELD2
Neuroticism (2016) 1.56 1 0 0.0 0.00 1.0e+00 THOC7
Schizophrenia (2014) 15.97 42 32 71.1 1.00 1.8e-43 AC011816.1 AC103965.1 ACTR5 AKT3 ANKRD44 AS3MT ATG13 BAI1 C12orf65 C17orf39 C2orf47 CACNA2D4 CEP170 CHRNA5 CLCN3 CNTN4 CRELD2 CUL3 DCP1B ELAC2 ERCC8 FAM53C FAM83H FES HSPD1 IK IMMP2L ITIH4-AS1 KIAA0319 LGSN MAP7D1 MAPK3 MGAT3 NAGA PCCB PCNX PPP1R13B PPP1R14B SDCCAG8 SLCO4C1 THOC7 VPS29
Blood Eosinophil Count 0.81 5 3 6.7 0.66 2.3e-01 AC103965.1 C17orf39 ITIH4-AS1 MAPK3 PPP1R13B
Blood Platelet Count 1.08 11 6 13.3 -0.39 2.3e-01 AC011816.1 AC103965.1 ANKRD44 AS3MT C12orf65 CRELD2 HSPD1 ITIH4-AS1 KIAA0319 MAP7D1 PCCB
Blood Red Count 1.38 9 4 8.9 0.48 1.9e-01 ANKRD44 AS3MT C12orf65 C17orf39 C2orf47 ITIH4-AS1 LGSN MAPK3 VPS29
Blood White Count 1.12 11 5 11.1 0.55 8.1e-02 AKT3 C17orf39 FES IK LGSN MAPK3 MGAT3 NAGA PCCB PPP1R13B THOC7
Heel T-Score 1.05 4 3 6.7 0.71 2.9e-01 ATG13 CRELD2 MAPK3 PPP1R13B
BMI 2.49 10 6 13.3 -0.50 1.4e-01 AKT3 AS3MT ATG13 BAI1 C2orf47 ITIH4-AS1 LGSN MAPK3 PPP1R13B VPS29
Height 1.29 18 12 26.7 -0.35 1.5e-01 AC103965.1 AS3MT C12orf65 C17orf39 CEP170 CRELD2 FAM83H FES IK ITIH4-AS1 MAP7D1 MAPK3 MGAT3 PCCB PPP1R13B SDCCAG8 SLCO4C1 THOC7
Waist Hip Ratio (WHR) 2.32 10 4 8.9 0.26 4.7e-01 AC103965.1 C12orf65 C17orf39 ERCC8 FAM53C ITIH4-AS1 MGAT3 PCCB PCNX SLCO4C1
Systolic Blood Pressure 2.98 9 6 13.3 0.05 8.9e-01 AS3MT C17orf39 C2orf47 FES IK PCNX PPP1R14B SDCCAG8 VPS29
Smoking Status 2.88 4 2 4.4 0.19 8.1e-01 AS3MT CUL3 ERCC8 PPP1R13B
Allergy or Eczema 1.92 3 2 4.4 0.00 1.0e+00 ANKRD44 C17orf39 HSPD1
Cardiovascular Disease 2.42 6 2 4.4 -0.38 4.5e-01 AS3MT FES PCCB PCNX PPP1R13B SDCCAG8
Respiratory disease 1.16 1 0 0.0 0.00 1.0e+00 ANKRD44
Lung FEV1/FVC ratio 1.21 5 2 4.4 -0.51 3.8e-01 AC103965.1 C17orf39 CHRNA5 ITIH4-AS1 MAPK3
Lung FVC 1.04 4 1 2.2 -0.35 6.5e-01 C17orf39 CHRNA5 CUL3 IK
Neuroticism 1.96 3 2 4.4 0.00 1.0e+00 AS3MT CRELD2 PCCB
Hair Pigment 0.17 4 3 6.7 0.56 4.4e-01 FAM53C FES PCNX PPP1R13B
Tanning 0.30 3 0 0.0 0.00 1.0e+00 CRELD2 ERCC8 ITIH4-AS1
Hand grip strength (left) 1.25 3 0 0.0 0.00 1.0e+00 AS3MT MAPK3 NAGA
Number of treatments/medications taken 1.60 1 1 2.2 0.00 1.0e+00 FES
Sensitivity / hurt feelings 1.30 1 0 0.0 0.00 1.0e+00 PCCB
Frequency of depressed mood in last 2 weeks 1.64 1 0 0.0 0.00 1.0e+00 PCCB
Hearing difficulty/problems: Yes 1.78 1 0 0.0 0.00 1.0e+00 AKT3
Relative age of first facial hair 1.59 2 1 2.2 0.00 1.0e+00 AKT3 CEP170
Systolic blood pressure, automated reading 2.32 3 2 4.4 0.00 1.0e+00 AS3MT FES PPP1R14B
Angina 1.38 1 1 2.2 0.00 1.0e+00 FES
Pack years adult smoking proportion 4.77 2 1 2.2 0.00 1.0e+00 CHRNA5 PPP1R13B
Impedance of leg (right) 2.91 9 6 13.3 0.22 5.6e-01 AC103965.1 AS3MT C17orf39 C2orf47 ERCC8 ITIH4-AS1 MAP7D1 MAPK3 PPP1R13B
Leg fat-free mass (left) 2.34 11 4 8.9 -0.70 1.7e-02 AS3MT ATG13 C2orf47 CEP170 ERCC8 FAM83H MAP7D1 MAPK3 MGAT3 TRIM38 VPS29
Trunk fat percentage 1.74 4 2 4.4 -0.50 5.0e-01 AC103965.1 ANKRD44 MAPK3 TRIM38
Hand grip strength (right) 0.87 1 0 0.0 0.00 1.0e+00 NAGA
Current tobacco smoking 2.27 4 0 0.0 0.27 7.3e-01 AS3MT CHRNA5 CUL3 PPP1R13B
Maternal smoking around birth 2.41 3 1 2.2 0.00 1.0e+00 AS3MT CHRNA5 PPP1R13B
Fed-up feelings 1.86 1 1 2.2 0.00 1.0e+00 PCCB
Frequency of unenthusiasm / disinterest in last 2 weeks 1.91 1 0 0.0 0.00 1.0e+00 PCCB
Age when periods started (menarche) 1.48 2 1 2.2 0.00 1.0e+00 AKT3 MAPK3
Heel bone mineral density (BMD) T-score, automated (left) 1.20 1 0 0.0 0.00 1.0e+00 ATG13
High blood pressure 2.52 4 1 2.2 -0.95 4.9e-02 FES PCNX PPP1R14B SDCCAG8
Hayfever, allergic rhinitis or eczema 1.59 2 2 4.4 0.00 1.0e+00 ANKRD44 HSPD1
Multivitamins +/- minerals 1.96 1 0 0.0 0.00 1.0e+00 BAI1
Medication: Atenolol 1.54 1 1 2.2 0.00 1.0e+00 FES
Sitting height 1.20 9 4 8.9 -0.54 1.3e-01 AC103965.1 AKT3 C12orf65 C17orf39 FAM53C FAM83H IK MGAT3 THOC7
Chronic bronchitis/emphysema (father) 2.16 1 1 2.2 0.00 1.0e+00 CHRNA5
High blood pressure (mother) 2.26 1 1 2.2 0.00 1.0e+00 FES
Body mass index (BMI) 2.29 9 4 8.9 -0.68 4.3e-02 AS3MT ATG13 BAI1 C2orf47 ITIH4-AS1 MAPK3 PPP1R13B TRIM38 VPS29
Impedance of leg (left) 2.80 9 6 13.3 0.22 5.7e-01 AC103965.1 AS3MT C17orf39 ERCC8 ITIH4-AS1 MAP7D1 MAPK3 MGAT3 PPP1R13B
Leg predicted mass (left) 2.34 11 4 8.9 -0.69 1.9e-02 AS3MT ATG13 C2orf47 CEP170 ERCC8 FAM83H MAP7D1 MAPK3 MGAT3 TRIM38 VPS29
Trunk fat mass 2.08 6 3 6.7 -0.86 2.8e-02 AC103965.1 AS3MT C2orf47 FAM83H MAPK3 TRIM38
Waist circumference 2.28 5 1 2.2 -0.69 1.9e-01 AS3MT BAI1 C2orf47 MAPK3 PPP1R13B
Number of incorrect matches in round 2.74 2 1 2.2 0.00 1.0e+00 AS3MT MAPK3
Past tobacco smoking 2.22 1 1 2.2 0.00 1.0e+00 AS3MT
Alcohol usually taken with meals 1.77 1 0 0.0 0.00 1.0e+00 ERCC8
Nervous feelings 2.82 4 4 8.9 0.99 6.2e-03 AS3MT ITIH4-AS1 MAPK3 PCCB
Frequency of tenseness / restlessness in last 2 weeks 2.28 1 1 2.2 0.00 1.0e+00 PCCB
Hearing difficulty/problems with background noise 1.83 1 0 0.0 0.00 1.0e+00 PPP1R13B
Forced vital capacity (FVC) 1.58 7 1 2.2 -0.05 9.1e-01 AC103965.1 CEP170 CHRNA5 CUL3 IK TRIM38 U91328.21
Heel bone mineral density (BMD) T-score, automated (right) 1.24 2 0 0.0 0.00 1.0e+00 ATG13 KIAA0319
Qualifications: None of the above 1.56 1 1 2.2 0.00 1.0e+00 ERCC8
Financial difficulties in last 2 years 1.47 1 1 2.2 0.00 1.0e+00 PPP1R13B
Mouth/teeth dental problems 1.60 1 0 0.0 0.00 1.0e+00 PPP1R13B
Heart attack 1.65 1 0 0.0 0.00 1.0e+00 FES
Allergy 1.32 2 2 4.4 0.00 1.0e+00 ANKRD44 HSPD1
Medication: Ramipril 2.20 1 0 0.0 0.00 1.0e+00 FES
Medication: Simvastatin 1.27 1 0 0.0 0.00 1.0e+00 FES
Fluid intelligence score 2.45 4 1 2.2 -0.60 4.0e-01 C12orf65 MGAT3 PCCB U91328.21
Illnesses of siblings 1.06 1 0 0.0 0.00 1.0e+00 FES
Neuroticism score 1.70 1 1 2.2 0.00 1.0e+00 PCCB
Weight 2.42 8 2 4.4 -0.75 3.2e-02 AC103965.1 AS3MT C2orf47 FAM83H MAP7D1 MAPK3 TRIM38 VPS29
Impedance of arm (right) 2.52 9 5 11.1 0.65 5.7e-02 AC103965.1 ANKRD44 AS3MT ERCC8 FAM53C HSPD1 ITIH4-AS1 MAPK3 VPS29
Arm fat percentage (right) 1.75 6 1 2.2 -0.52 2.9e-01 ANKRD44 AS3MT ATG13 C2orf47 MAPK3 PPP1R13B
Trunk fat-free mass 2.05 9 5 11.1 -0.68 4.2e-02 AS3MT ERCC8 FAM53C FAM83H HSPD1 MAP7D1 MAPK3 MGAT3 VPS29
Hip circumference 2.50 9 4 8.9 -0.89 1.2e-03 AC103965.1 AS3MT BAI1 ERCC8 FAM83H ITIH4-AS1 MAPK3 TRIM38 VPS29
Alcohol intake versus 10 years previously 1.10 1 0 0.0 0.00 1.0e+00 MAPK3
Father's age at death 1.58 2 1 2.2 0.00 1.0e+00 CHRNA5 FES
Worrier / anxious feelings 2.93 5 3 6.7 0.98 4.5e-03 AS3MT C2orf47 CACNA2D4 ITIH4-AS1 PCCB
Frequency of tiredness / lethargy in last 2 weeks 2.05 1 0 0.0 0.00 1.0e+00 PPP1R13B
Number of live births 1.67 1 0 0.0 0.00 1.0e+00 FAM83H
Forced expiratory volume in 1-second (FEV1) 1.99 6 5 11.1 -0.40 4.3e-01 AC103965.1 CEP170 CHRNA5 IK TRIM38 U91328.21
Pulse rate 1.48 2 0 0.0 0.00 1.0e+00 C17orf39 ITIH4-AS1
Qualifications: A levels/AS levels or equivalent 1.63 3 0 0.0 0.00 1.0e+00 C12orf65 ERCC8 MGAT3
Mouth/teeth dental problems: Dentures 2.24 2 0 0.0 0.00 1.0e+00 CHRNA5 TRIM38
Asthma 1.77 2 1 2.2 0.00 1.0e+00 TRIM38 U91328.21
Medication: Ibuprofen (e.g. Nurofen) 1.95 1 0 0.0 0.00 1.0e+00 U91328.21
Medication: Cholesterol lowering 1.51 1 1 2.2 0.00 1.0e+00 FES
Lung cancer (father) 2.12 1 1 2.2 0.00 1.0e+00 CHRNA5
Illnesses of mother 1.57 1 1 2.2 0.00 1.0e+00 FES
Forced expiratory volume in 1-second (FEV1), Best measure 1.93 6 4 8.9 -0.41 4.2e-01 AC103965.1 CEP170 CHRNA5 IK TRIM38 U91328.21
Impedance of arm (left) 2.53 9 5 11.1 0.56 1.2e-01 AC103965.1 ANKRD44 AS3MT ERCC8 HSPD1 ITIH4-AS1 MAPK3 NAGA VPS29
Arm fat mass (right) 2.16 8 1 2.2 -0.67 6.9e-02 AS3MT ATG13 BAI1 C2orf47 MAPK3 PPP1R13B TRIM38 VPS29
Trunk predicted mass 2.04 9 5 11.1 -0.69 4.2e-02 AS3MT ERCC8 FAM53C FAM83H HSPD1 MAP7D1 MAPK3 MGAT3 VPS29
Standing height 1.26 12 3 6.7 -0.31 3.3e-01 AC103965.1 AS3MT C17orf39 CEP170 FAM83H IK ITIH4-AS1 MAPK3 MGAT3 SDCCAG8 SLCO4C1 U91328.21
Tense / 'highly strung' 2.15 3 0 0.0 0.00 1.0e+00 CACNA2D4 MAPK3 PCCB
Seen doctor (GP) for nerves, anxiety, tension or depression 2.36 2 0 0.0 0.00 1.0e+00 ACTR5 U91328.21
Birth weight of first child 1.91 2 1 2.2 0.00 1.0e+00 AS3MT FES
Peak expiratory flow (PEF) 1.13 1 0 0.0 0.00 1.0e+00 U91328.21
Qualifications: O levels/GCSEs or equivalent 1.57 1 0 0.0 0.00 1.0e+00 C12orf65
Medication: Paracetamol 2.57 2 1 2.2 0.00 1.0e+00 SDCCAG8 U91328.21
Headache pain in last month 2.48 3 3 6.7 0.00 1.0e+00 CEP170 SDCCAG8 U91328.21
Medication for cholesterol, blood pressure or diabetes 2.35 2 1 2.2 0.00 1.0e+00 FES PCNX
Medication: Amlodipine 1.78 1 1 2.2 0.00 1.0e+00 FES
Birth weight 1.58 2 1 2.2 0.00 1.0e+00 AS3MT FES
Chronic bronchitis/emphysema (mother) 1.53 1 1 2.2 0.00 1.0e+00 CHRNA5
High blood pressure (siblings) 1.17 1 0 0.0 0.00 1.0e+00 FES
Forced vital capacity (FVC), Best measure 1.45 6 2 4.4 0.29 5.8e-01 AC103965.1 CEP170 CUL3 IK TRIM38 U91328.21
Body fat percentage 1.67 4 2 4.4 -0.60 4.0e-01 AC103965.1 ANKRD44 MAPK3 TRIM38
Leg fat percentage (right) 1.47 3 1 2.2 0.00 1.0e+00 AC103965.1 MAPK3 TRIM38
Arm fat-free mass (right) 2.24 9 4 8.9 -0.73 2.7e-02 AS3MT ERCC8 FAM53C FAM83H HSPD1 MAP7D1 MAPK3 MGAT3 VPS29
Comparative body size at age 10 1.82 3 1 2.2 0.00 1.0e+00 ERCC8 MAPK3 U91328.21
Worry too long after embarrassment 1.72 1 1 2.2 0.00 1.0e+00 PCCB
Seen a psychiatrist for nerves, anxiety, tension or depression 2.67 2 0 0.0 0.00 1.0e+00 ACTR5 TRIM38
Wheeze or whistling in the chest in last year 1.19 1 0 0.0 0.00 1.0e+00 MAPK3
Reason for reducing amount of alcohol drunk: Health precaution 1.86 1 0 0.0 0.00 1.0e+00 ACTR5
Qualifications: College or University degree 1.85 4 2 4.4 -0.13 8.7e-01 C12orf65 CEP170 ERCC8 MGAT3
Medication for pain relief, constipation, heartburn 2.64 3 1 2.2 0.00 1.0e+00 PCNX SDCCAG8 U91328.21
Medication: Blood pressure 2.45 2 1 2.2 0.00 1.0e+00 FES KIAA0319
Angina (self-reported) 1.39 1 1 2.2 0.00 1.0e+00 FES
Mean time to correctly identify matches 2.10 2 1 2.2 0.00 1.0e+00 ATG13 IMMP2L
Heart disease (mother) 1.91 1 0 0.0 0.00 1.0e+00 MAP7D1
Whole body fat mass 2.11 6 3 6.7 -0.83 4.1e-02 AC103965.1 AS3MT C2orf47 FAM83H MAPK3 TRIM38
Leg fat mass (right) 2.06 6 3 6.7 -0.89 1.7e-02 AC103965.1 AS3MT ITIH4-AS1 MAPK3 TRIM38 VPS29
Arm predicted mass (right) 2.23 8 3 6.7 -0.85 7.0e-03 AS3MT ERCC8 FAM53C FAM83H HSPD1 MAPK3 MGAT3 VPS29
Pulse rate, automated reading 1.48 3 1 2.2 0.00 1.0e+00 C17orf39 ITIH4-AS1 VPS29
Alcohol intake frequency. 1.02 3 0 0.0 0.00 1.0e+00 BAI1 CHRNA5 MAPK3
Comparative height size at age 10 1.92 10 5 11.1 0.09 8.1e-01 AC103965.1 CRELD2 FAM83H FES ITIH4-AS1 MAP7D1 MAPK3 PCCB SLCO4C1 U91328.21
Suffer from 'nerves' 2.00 1 0 0.0 0.00 1.0e+00 AS3MT
Overall health rating 1.69 1 0 0.0 0.00 1.0e+00 C17orf39
Leg pain on walking 1.18 1 0 0.0 0.00 1.0e+00 PCNX
Illness, injury, bereavement, stress in last 2 years 1.36 1 0 0.0 0.00 1.0e+00 PPP1R13B
Medication: Aspirin 1.32 1 1 2.2 0.00 1.0e+00 FES
Hypertension (Self-reported) 2.53 4 1 2.2 -0.96 4.2e-02 FES PCNX PPP1R14B SDCCAG8
Illnesses of father: Heart disease 1.81 1 1 2.2 0.00 1.0e+00 FES
Smoking status: Previous 1.61 1 0 0.0 0.00 1.0e+00 KIAA0319
Forced expiratory volume in 1-second (FEV1), predicted 1.39 1 1 2.2 0.00 1.0e+00 AC103965.1
Whole body fat-free mass 2.22 11 4 8.9 -0.73 1.1e-02 AS3MT C2orf47 CEP170 ERCC8 FAM53C FAM83H IK MAP7D1 MAPK3 MGAT3 VPS29
Leg fat-free mass (right) 2.35 10 3 6.7 -0.75 1.3e-02 AS3MT C2orf47 CEP170 ERCC8 FAM83H IK MAP7D1 MAPK3 MGAT3 VPS29
Arm fat percentage (left) 1.75 7 1 2.2 -0.50 2.5e-01 ANKRD44 AS3MT ATG13 C2orf47 MAPK3 PPP1R13B TRIM38
Long-standing illness, disability or infirmity 1.49 1 0 0.0 0.00 1.0e+00 PPP1R13B
Qualifications: nursing, teaching 1.54 1 0 0.0 0.00 1.0e+00 ERCC8
Medication for cholesterol 1.16 1 0 0.0 0.00 1.0e+00 FES
Mineral and other dietary supplements 1.61 1 0 0.0 0.00 1.0e+00 BAI1
Asthma (self-reported) 1.71 2 1 2.2 0.00 1.0e+00 TRIM38 U91328.21
Medication: Aspirin 1.57 1 1 2.2 0.00 1.0e+00 FES
Illnesses of father: None of the above (group 1) 2.46 1 1 2.2 0.00 1.0e+00 FES
Smoking status: Current 2.09 3 0 0.0 0.00 1.0e+00 AS3MT CUL3 PPP1R13B
Forced expiratory volume in 1-second (FEV1), predicted percentage 2.02 4 3 6.7 -0.28 7.2e-01 CHRNA5 MAPK3 TRIM38 U91328.21
Whole body water mass 2.23 11 5 11.1 -0.73 1.1e-02 AS3MT C2orf47 CEP170 ERCC8 FAM53C FAM83H IK MAP7D1 MAPK3 MGAT3 VPS29
Leg predicted mass (right) 2.33 10 3 6.7 -0.75 1.3e-02 AS3MT C2orf47 CEP170 ERCC8 FAM83H IK MAP7D1 MAPK3 MGAT3 VPS29
Arm fat mass (left) 2.26 9 2 4.4 -0.70 3.7e-02 AS3MT ATG13 BAI1 C2orf47 ITIH4-AS1 MAPK3 PPP1R13B TRIM38 VPS29
Miserableness 1.46 1 0 0.0 0.00 1.0e+00 CEP170
Guilty feelings 1.65 1 0 0.0 0.00 1.0e+00 KIAA0319
Hearing aid user 1.82 1 0 0.0 0.00 1.0e+00 ERCC8
Medication: Blood pressure 1.69 1 1 2.2 0.00 1.0e+00 FES
High cholesterol (Self-reported) 1.09 1 0 0.0 0.00 1.0e+00 PCNX
Medication: Bendroflumethiazide 1.58 1 0 0.0 0.00 1.0e+00 FES
Medication: Paracetamol 2.14 1 0 0.0 0.00 1.0e+00 U91328.21
Illnesses of father: High blood pressure 2.38 1 1 2.2 0.00 1.0e+00 FES
Ever smoked 2.52 1 0 0.0 0.00 1.0e+00 AS3MT
Basal metabolic rate 2.32 10 4 8.9 -0.74 1.5e-02 AS3MT C2orf47 CEP170 ERCC8 FAM83H IK MAP7D1 MAPK3 MGAT3 VPS29
Leg fat percentage (left) 1.53 3 1 2.2 0.00 1.0e+00 AC103965.1 MAPK3 TRIM38
Arm fat-free mass (left) 2.29 9 3 6.7 -0.70 3.6e-02 AS3MT ERCC8 FAM53C FAM83H HSPD1 MAP7D1 MAPK3 MGAT3 VPS29
Number of operations (self-reported) 1.64 1 0 0.0 0.00 1.0e+00 ERCC8
Risk taking 4.16 4 2 4.4 0.68 3.2e-01 AKT3 CEP170 PCCB PPP1R13B
Ever had prostate specific antigen (PSA) test 1.17 1 0 0.0 0.00 1.0e+00 U91328.21
Diastolic blood pressure, automated reading 2.68 6 4 8.9 -0.41 4.1e-01 C12orf65 CEP170 FES PPP1R13B SDCCAG8 U91328.21
Ever depressed for a whole week 2.08 1 0 0.0 0.00 1.0e+00 AKT3
Vascular/heart problems diagnosed by doctor 2.70 5 1 2.2 0.28 6.5e-01 AS3MT FES PCNX PPP1R13B PPP1R14B
Pain experienced in last month 1.26 1 0 0.0 0.00 1.0e+00 CUL3
Heart attack/myocardial infarction (self-reported) 1.64 1 0 0.0 0.00 1.0e+00 FES
Alcohol drinker status: Previous 1.92 1 0 0.0 0.00 1.0e+00 PPP1R13B
Pack years of smoking 4.33 2 1 2.2 0.00 1.0e+00 CHRNA5 PPP1R13B
Impedance of whole body 2.87 11 7 15.6 0.38 2.5e-01 AC103965.1 ANKRD44 AS3MT CACNA2D4 ERCC8 HSPD1 ITIH4-AS1 MAP7D1 MAPK3 PPP1R13B VPS29
Leg fat mass (left) 2.15 8 3 6.7 -0.80 1.8e-02 AC103965.1 AS3MT ATG13 C2orf47 ITIH4-AS1 MAPK3 TRIM38 VPS29
Arm predicted mass (left) 2.26 8 2 4.4 -0.71 4.9e-02 AS3MT ERCC8 FAM83H HSPD1 MAP7D1 MAPK3 MGAT3 VPS29

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 14 0.41 2.2
GTEx Adipose Visceral Omentum 5 0.25 2.2
GTEx Adrenal Gland 5 0.35 2.1
GTEx Artery Aorta 11 0.38 2.2
GTEx Artery Coronary 2 0.17 2.2
GTEx Artery Tibial 14 0.38 2.2
GTEx Brain Caudate basal ganglia 3 0.33 2.2
GTEx Brain Cerebellar Hemisphere 3 0.21 2.1
GTEx Brain Cerebellum 2 0.10 2.4
GTEx Brain Cortex 6 0.59 2.3
GTEx Brain Frontal Cortex BA9 2 0.22 2.2
GTEx Brain Hippocampus 0 0.00 2.2
GTEx Brain Hypothalamus 2 0.35 2.1
GTEx Brain Nucleus accumbens basal ganglia 1 0.12 2.1
GTEx Brain Putamen basal ganglia 1 0.16 2.1
GTEx Breast Mammary Tissue 12 0.63 2.4
GTEx Breast Mammary Tissue (Male) 6 0.52 2.3
GTEx Breast Mammary Tissue (Female) 6 0.38 2.2
GTEx Cells EBV-transformed lymphocytes 8 0.58 2.3
GTEx Cells Transformed fibroblasts 16 0.39 2.2
GTEx Colon Sigmoid 6 0.42 2.2
GTEx Colon Transverse 5 0.25 2.3
GTEx Esophagus Gastroesophageal Junction 7 0.50 2.2
GTEx Esophagus Mucosa 11 0.34 2.3
GTEx Esophagus Muscularis 15 0.48 2.2
GTEx Heart Atrial Appendage 3 0.19 2.2
GTEx Heart Left Ventricle 5 0.34 2.2
GTEx Liver 4 0.57 2.3
GTEx Lung 7 0.25 2.2
GTEx Muscle Skeletal 6 0.21 2.1
GTEx Nerve Tibial 13 0.31 2.1
GTEx Ovary 3 0.34 2.3
GTEx Pancreas 6 0.38 2.4
GTEx Pituitary 4 0.37 2.2
GTEx Prostate 4 0.49 2.5
GTEx Skin Not Sun Exposed Suprapubic 9 0.37 2.2
GTEx Skin Sun Exposed Lower leg 9 0.25 2.2
GTEx Small Intestine Terminal Ileum 1 0.22 2.3
GTEx Spleen 5 0.36 2.2
GTEx Stomach 4 0.28 2.1
GTEx Testis 22 0.71 2.3
GTEx Thyroid 16 0.41 2.2
GTEx Uterus 1 0.18 2.1
GTEx Vagina 2 0.32 2.0
GTEx Whole Blood 8 0.41 2.2
METSIM Adipose 8 0.18 2.0
NTR Blood 6 0.25 2.0
ROSMAP Brain Pre-frontal Cortex 13 0.30 2.2
YFS Blood 12 0.26 2.0
CommonMind Brain Pre-frontal Cortex 15 0.28 2.2
The Cancer Genome Atlas Bladder Urothelial Carcinoma 8 0.51 2.2
The Cancer Genome Atlas Breast Invasive Carcinoma 8 0.19 2.1
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 2 0.19 2.1
The Cancer Genome Atlas Colon Adenocarcinoma 6 0.31 2.1
The Cancer Genome Atlas Esophageal Carcinoma 2 0.30 2.2
The Cancer Genome Atlas Glioblastoma Multiforme 5 0.51 2.2
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 4 0.15 2.0
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 9 0.23 2.1
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 9 0.46 2.1
The Cancer Genome Atlas Brain Lower Grade Glioma 6 0.15 2.1
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 3 0.28 2.0
The Cancer Genome Atlas Lung Adenocarcinoma 9 0.32 2.1
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 7 0.29 2.1
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 6 0.39 2.1
The Cancer Genome Atlas Pancreatic Adenocarcinoma 2 0.13 2.1
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 4 0.32 2.1
The Cancer Genome Atlas Prostate Adenocarcinoma 9 0.20 2.1
The Cancer Genome Atlas Rectum Adenocarcinoma 2 0.30 2.0
The Cancer Genome Atlas Soft Tissue Sarcoma 2 0.20 2.1
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.00 1.9
The Cancer Genome Atlas Stomach Adenocarcinoma 4 0.25 2.2
The Cancer Genome Atlas Testicular Germ Cell Tumors 6 0.49 2.0
The Cancer Genome Atlas Thyroid Carcinoma 20 0.40 2.1
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.00 1.7